Cargando…

Clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study

INTRODUCTION: Deep brain stimulation (DBS) is a new potential surgical treatment for opioid dependence. However, the implement of DBS treatment in addicted patients is currently controversial due to the significant associated risks. The aim of this study was mainly to investigate the therapeutic eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Liang, Ge, Shunnan, Li, Nan, Wang, Wei, Yang, Kaijun, Wu, Ping, Wang, Xuelian, Shi, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398661/
https://www.ncbi.nlm.nih.gov/pubmed/30765398
http://dx.doi.org/10.1136/bmjopen-2018-023516
_version_ 1783399617138786304
author Qu, Liang
Ge, Shunnan
Li, Nan
Wang, Wei
Yang, Kaijun
Wu, Ping
Wang, Xuelian
Shi, Jie
author_facet Qu, Liang
Ge, Shunnan
Li, Nan
Wang, Wei
Yang, Kaijun
Wu, Ping
Wang, Xuelian
Shi, Jie
author_sort Qu, Liang
collection PubMed
description INTRODUCTION: Deep brain stimulation (DBS) is a new potential surgical treatment for opioid dependence. However, the implement of DBS treatment in addicted patients is currently controversial due to the significant associated risks. The aim of this study was mainly to investigate the therapeutic efficacy and safety of bilateral DBS of nucleus accumbens and the anterior limb of the internal capsule (NAc/ALIC-DBS) in patients with refractory opioid dependence (ROD). METHODS AND ANALYSIS: 60 patients with ROD will be enrolled in this multicentre, prospective, double-blinded study, and will be followed up for 25 weeks (6 months) after surgery. Patients with ROD (semisynthetic opioids) who meet the criteria for NAc/ALIC-DBS surgery will be allocated to either the early stimulation group or the late stimulation group (control group) based on the randomised ID number. The primary outcome was defined as the abstinence rate at 25 weeks after DBS stimulation on, which will be confirmed by an opiate urine tests. The secondary outcomes include changes in the Visual Analogue Scale (VAS) score for craving for opioid drugs, body weight, as well as psychological evaluation measured using the 17-item Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, the Pittsburgh Sleep Quality Index, Fagerstrom test for nicotine dependence assessment, social disability screening schedule, the Activity of Daily Living Scale, the 36-item Short Form-Health Survey and safety profiles of both groups. ETHICS AND DISSEMINATION: The study received ethical approval from the medical ethical committee of Tangdu Hospital, The Fourth Military Medical University, Xi’an, China. The results of this study will be published in a peer-reviewed journal and presented at international conferences. TRIAL REGISTRATION NUMBER: NCT03424616; Pre-results.
format Online
Article
Text
id pubmed-6398661
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-63986612019-03-20 Clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study Qu, Liang Ge, Shunnan Li, Nan Wang, Wei Yang, Kaijun Wu, Ping Wang, Xuelian Shi, Jie BMJ Open Addiction INTRODUCTION: Deep brain stimulation (DBS) is a new potential surgical treatment for opioid dependence. However, the implement of DBS treatment in addicted patients is currently controversial due to the significant associated risks. The aim of this study was mainly to investigate the therapeutic efficacy and safety of bilateral DBS of nucleus accumbens and the anterior limb of the internal capsule (NAc/ALIC-DBS) in patients with refractory opioid dependence (ROD). METHODS AND ANALYSIS: 60 patients with ROD will be enrolled in this multicentre, prospective, double-blinded study, and will be followed up for 25 weeks (6 months) after surgery. Patients with ROD (semisynthetic opioids) who meet the criteria for NAc/ALIC-DBS surgery will be allocated to either the early stimulation group or the late stimulation group (control group) based on the randomised ID number. The primary outcome was defined as the abstinence rate at 25 weeks after DBS stimulation on, which will be confirmed by an opiate urine tests. The secondary outcomes include changes in the Visual Analogue Scale (VAS) score for craving for opioid drugs, body weight, as well as psychological evaluation measured using the 17-item Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, the Pittsburgh Sleep Quality Index, Fagerstrom test for nicotine dependence assessment, social disability screening schedule, the Activity of Daily Living Scale, the 36-item Short Form-Health Survey and safety profiles of both groups. ETHICS AND DISSEMINATION: The study received ethical approval from the medical ethical committee of Tangdu Hospital, The Fourth Military Medical University, Xi’an, China. The results of this study will be published in a peer-reviewed journal and presented at international conferences. TRIAL REGISTRATION NUMBER: NCT03424616; Pre-results. BMJ Publishing Group 2019-02-13 /pmc/articles/PMC6398661/ /pubmed/30765398 http://dx.doi.org/10.1136/bmjopen-2018-023516 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Addiction
Qu, Liang
Ge, Shunnan
Li, Nan
Wang, Wei
Yang, Kaijun
Wu, Ping
Wang, Xuelian
Shi, Jie
Clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study
title Clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study
title_full Clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study
title_fullStr Clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study
title_full_unstemmed Clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study
title_short Clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study
title_sort clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study
topic Addiction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398661/
https://www.ncbi.nlm.nih.gov/pubmed/30765398
http://dx.doi.org/10.1136/bmjopen-2018-023516
work_keys_str_mv AT quliang clinicalevaluationofdeepbrainstimulationofnucleusaccumbensanteriorlimbofinternalcapsuleforopioidrelapsepreventionprotocolofamulticentreprospectiveanddoubleblindedstudy
AT geshunnan clinicalevaluationofdeepbrainstimulationofnucleusaccumbensanteriorlimbofinternalcapsuleforopioidrelapsepreventionprotocolofamulticentreprospectiveanddoubleblindedstudy
AT linan clinicalevaluationofdeepbrainstimulationofnucleusaccumbensanteriorlimbofinternalcapsuleforopioidrelapsepreventionprotocolofamulticentreprospectiveanddoubleblindedstudy
AT wangwei clinicalevaluationofdeepbrainstimulationofnucleusaccumbensanteriorlimbofinternalcapsuleforopioidrelapsepreventionprotocolofamulticentreprospectiveanddoubleblindedstudy
AT yangkaijun clinicalevaluationofdeepbrainstimulationofnucleusaccumbensanteriorlimbofinternalcapsuleforopioidrelapsepreventionprotocolofamulticentreprospectiveanddoubleblindedstudy
AT wuping clinicalevaluationofdeepbrainstimulationofnucleusaccumbensanteriorlimbofinternalcapsuleforopioidrelapsepreventionprotocolofamulticentreprospectiveanddoubleblindedstudy
AT wangxuelian clinicalevaluationofdeepbrainstimulationofnucleusaccumbensanteriorlimbofinternalcapsuleforopioidrelapsepreventionprotocolofamulticentreprospectiveanddoubleblindedstudy
AT shijie clinicalevaluationofdeepbrainstimulationofnucleusaccumbensanteriorlimbofinternalcapsuleforopioidrelapsepreventionprotocolofamulticentreprospectiveanddoubleblindedstudy